VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IQV
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
IQVIQVIA Holdings Inc.
$193.28$32.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksIQVCash Flow

IQVIA Holdings Inc. (IQV) Cash Flow Statement

15Y historyFree accessUpdated daily

Free cash flow margins exhibit significant lumpiness, ranging from 7.3% to 29.3%, though operating cash flow consistently outpaces net income with an OCF/NI ratio as high as 2.74.

IQV Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Cash from Operations2.7B2.65B2.72B2.15B2.26B2.94B1.96B1.42B1.25B970M860M475.69M431.75M397.37M335.7M160.95M
Operating CF Margin %-16.27%17.63%14.34%15.68%21.21%17.25%12.78%12.04%10%12.62%8.29%7.91%7.79%6.9%3.72%
Operating CF Growth %-6.87%-2.28%26.38%-4.91%-23.18%50.18%38.25%13%29.28%12.79%80.79%10.18%8.65%18.37%108.57%-
Net Income1.39B1.36B1.37B1.36B1.09B966M308M227M284M1.33B130M388.3M356.5M226.03M176.63M240.33M
Depreciation & Amortization1.17B1.14B1.11B1.13B1.13B1.26B1.29B1.2B1.14B1.01B289M127.74M121.01M107.5M98.29M92M
Stock-Based Compensation180M247M206M217M194M170M95M146M113M106M80M37.76M30M22.83M25.93M14.13M
Deferred Taxes-177M-180M-129M-269M-115M-138M-176M-157M-177M-1.22B135M18.35M-6.17M-24.24M16.59M-73.22M
Other Non-Cash Items-166M-43M-6M-2M44M0-14M-20M-1M33M14M-27.5M-23.73M5.47M5.8M-29.75M
Working Capital Changes313M125M158M-280M-84M680M459M19M-106M-292M212M-68.97M-45.86M59.78M12.46M-82.55M
Change in Receivables125M60M182M-388M-421M-138M255M-124M-297M-142M-62M-246.03M-78.63M-151.68M-60.26M-115.75M
Change in Inventory0000000-116M-184M-136M62M18.87M-32.98M32.56M-40.13M18.24M
Change in Payables0-96M115M267M427M244M253M240M368M90M160M104.35M45.8M107.05M58.34M67.38M
Cash from Investing-2.2B-2.31B-1.44B-1.6B-2.01B-2.1B-796M-1.19B-810M-1.19B1.73B-66.95M-173.11M-240.18M-132.23M-224.84M
Capital Expenditures-32M0-602M-649M-674M-640M-616M-582M-459M-369M-164M-78.39M-82.65M-92.35M-71.34M-75.68M
CapEx % of Revenue0.19%3.7%3.91%4.33%4.68%4.61%5.42%5.25%4.41%3.8%2.41%1.37%1.51%1.81%1.47%1.75%
Acquisitions-1.6B-1.71B-710M-876M-1.33B-1.46B-167M-588M-326M-827M1.87B19.38M-96.67M-149.99M-47.42M-135.82M
Investments----------------
Other Investing-540M-573M2M5M8M0-2M27M-457M2M24M551K-1.26M138K-182K16.37M
Cash from Financing-325M-150M-878M-382M-329M-1.24B-217M-276M-452M-72M-2.28B-249.25M-130.34M70.96M-146.87M-59.31M
Debt Issued (Net)1.24B1.21B553M802M941M70M342M747M1.01B2.51B-1.31B188M242M-387.66M440.14M260.12M
Equity Issued (Net)-456M-1.31B-1.35B-992M-1.17B-406M-447M-949M-1.41B-2.62B-1.1B-515M-415M-6.43M-10.25M-14.32M
Dividends Paid00000000000000-567.85M-288.32M
Share Repurchases-389M-1.24B-1.35B-992M-1.17B-406M-447M-949M-1.41B-2.62B-1.1B-515.01M-415M-6.43M-13.36M-14.32M
Other Financing-1.11B-44M-81M-192M-102M-899M-112M-74M-62M37M126M77.75M42.66M465.05M-8.91M-16.78M
Net Change in Cash207M278M326M160M-150M-448M977M-54M-68M-239M221M109.79M89.22M210.41M51.43M-130.32M
Free Cash Flow2.67B2.05B2.11B1.5B1.59B2.3B1.34B835M795M601M696M397.3M349.1M305.02M264.37M85.27M
FCF Margin %16.07%12.58%13.72%10.01%11.01%16.59%11.82%7.53%7.64%6.19%10.21%6.93%6.39%5.98%5.43%1.97%
FCF Growth %23.53%-2.98%40.93%-5.42%-31.1%71.41%60.84%5.03%32.28%-13.65%75.18%13.81%14.45%15.38%210.02%-
FCF per Share15.7411.8211.538.058.3211.816.894.183.822.704.583.162.662.392.070.67
FCF Conversion (FCF/Net Income)1.93x1.95x1.98x1.58x2.07x3.05x7.02x7.42x4.84x0.74x7.48x1.23x1.21x1.75x1.89x0.67x
Interest Paid00000000398M320M124M82M94M115.49M127.13M100.91M
Taxes Paid00295M340M255M222M00211M195M106M121M139M70.98M103.98M63.37M

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetMixed
Cash FlowStable
Top Statement Risk

Clinical trial backlog volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Operating Cash Flow Outpaces Earnings

As reported in financial statements, IQVIA consistently generates operating cash flow significantly higher than net income, with the OCF/NI ratio reaching as high as 2.74 in 2025Q3, suggesting that non-cash charges like amortization of intangibles play a substantial role in the company's reported GAAP profitability.

The persistent gap between net income and operating cash flow indicates that the company's accounting earnings are heavily impacted by non-cash expenses, likely stemming from the amortization of assets acquired during its aggressive M&A history. Investors should monitor this divergence, as it suggests that cash-generating power is more robust than the bottom-line GAAP figures imply.

Free Cash Flow Margin Volatility

Based on the provided quarterly data, IQVIA's free cash flow margins have fluctuated significantly, ranging from a low of 7.3% in 2025Q2 to a peak of 29.3% in 2025Q3, reflecting the inherent lumpiness of project-based clinical trial milestones and the timing of large-scale capital expenditures.

The inconsistency in FCF margins suggests that the company's ability to convert revenue into cash is highly sensitive to the timing of contract completions and the associated working capital swings. This volatility makes it difficult to project long-term cash flow stability, necessitating a cautious approach when evaluating the company's ability to fund future growth internally.

Capital Intensity Remains Relatively Controlled

According to recent SEC filings, IQVIA's capital expenditure as a percentage of revenue has remained relatively stable, generally hovering between 3.7% and 4.6% over the last ten quarters, which indicates that the business model does not require massive, recurring physical asset investment to maintain its current operations.

The relatively low capital intensity suggests that the company's primary investments are directed toward software development and data infrastructure rather than heavy machinery or physical facilities. While this supports a more asset-light model, investors should investigate whether this level of spending is sufficient to maintain the competitive edge of its proprietary data platforms against evolving technological threats.

Aggressive Capital Allocation Through Buybacks

As evidenced by the quarterly cash flow statements, IQVIA has prioritized share repurchases over other forms of capital return, with a notable $1.1 billion outflow in 2024Q4, while simultaneously maintaining a consistent pace of net acquisitions to bolster its integrated service and data offerings.

The company's reliance on share buybacks as a primary capital deployment tool suggests a management focus on offsetting dilution or supporting the share price, rather than returning cash to shareholders via dividends. This strategy warrants further investigation into whether these repurchases are providing adequate returns on invested capital compared to potential organic growth opportunities.

IQV — Frequently Asked Questions

Quick answers to the most common questions about buying IQV stock.

How much cash does IQVIA Holdings Inc. (IQV) generate from operations?

IQVIA Holdings Inc. (IQV) generated $2.65B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is IQVIA Holdings Inc.'s free cash flow?

IQVIA Holdings Inc. (IQV) generated $2.05B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is IQVIA Holdings Inc.'s capital expenditure (CapEx)?

IQVIA Holdings Inc. (IQV) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does IQVIA Holdings Inc. distribute cash to shareholders?

In 2025, IQVIA Holdings Inc. (IQV) spent $1.24B on share repurchases. This shows the company's commitment to returning capital to its equity investors.